Astrazeneca PLC Press Releases

AZN 
$68.9
*  
0.11
0.16%
Get AZN Alerts
*Delayed - data as of Feb. 27, 2015  -  Find a broker to begin trading AZN now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
CVS Health Announces Data from Smoking Cessation Outreach on One-Year Anniversary of Decision to Stop Tobacco Sales
2/5/2015 12:45:00 PM - PR Newswire


Actavis to Divest Rights to Branded Respiratory Portfolio in the U.S. and Canada to AstraZeneca
2/5/2015 2:05:00 AM - PR Newswire


AstraZeneca, MD Anderson Enter Collaboration to Help Improve Patient Outcomes in Ovarian/ Gynecologic Cancers
1/29/2015 12:44:00 PM - Business Wire


PEGASUS-TIMI 54 Study of BRILINTA® Meets Primary Endpoint in Both 60mg and 90mg Doses
1/14/2015 7:00:00 AM - Business Wire
▼-4.32 % Price Change since this news event. The Volume Ratio is 0.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


QIAGEN Announces First-ever Regulatory Registration of a Lung Cancer Companion Diagnostic Based on Liquid Biopsies
1/12/2015 2:00:00 AM - PR Newswire


Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference
1/8/2015 7:30:00 AM - PR Newswire


ADDC and AstraZeneca Collaborate to Support Five High Throughput Screening Proposals for New Therapeutic Targets
12/22/2014 9:00:00 AM - PR Newswire


LYNPARZA™ Approved By The US Food and Drug Administration For The Treatment Of Advanced Ovarian Cancer In Patients With Germline BRCA-mutations
12/19/2014 3:17:00 PM - PR Newswire


LYNPARZA™ Approved By The US Food and Drug Administration For The Treatment Of Advanced Ovarian Cancer In Patients With Germline BRCA-mutations
12/19/2014 3:17:00 PM - PR Newswire


Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
12/11/2014 4:01:00 PM - PR Newswire


Infinata’s BioPharm Insight 3Q14 Licensing League Table Report Reflects Robust Growth in Biotech, Pharmaceutical Industries
12/4/2014 3:00:00 PM - Business Wire
▼-7.02 % Price Change since this news event. The Volume Ratio is 1.43.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day